<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2744,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253, 103 U.S.P.Q.2d 1250 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/197e26ee0dd683c77a3d3514bd400d05'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/197e26ee0dd683c77a3d3514bd400d05'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1HUKN0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HUKN0003">Previous Result: <span>McMillin v. Foster City, No. C 11-03201 ...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1HUKNO003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HUKNO003">Next Result: <span>McFarland v. County of Santa Cruz, C-12-...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253, 103 U.S.P.Q.2d 1250 (Fed. Cir. 2012), Court Opinion'>
Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253, 103 U.S.P.Q.2d 1250 (Fed. Cir. 2012), Court...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253, 103 U.S.P.Q.2d 1250 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HUK5A003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Sciele Pharma Inc. v. Lupin Ltd.</div>
<div class='displayCitation'>103 U.S.P.Q.2d 1250</div>
<div class='displayCitation'>2012 BL 163766</div>
<div class='displayCitation'>684 F.3d 1253</div>
<div class='displayCitation'>bna a0d3k0u0q6</div>
<div class='displayCitation'>bna a0d3k7w1e8</div>
<div class='displayCitation'>bna a0d3n4h9u2</div>
<div class='displayCitation'>wkffecase:26191957</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HUK5A003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253, 103 U.S.P.Q.2d 1250 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Sciele Pharma Inc. v. Lupin Ltd." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1HUK5A003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HUK5A003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HUK5A003" /><input id="title" name="title" type="hidden" value="Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253, 103 U.S.P.Q.2d 1250 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="197e26ee0dd683c77a3d3514bd400d05" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HUK5A003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%31%39%37e%32%36ee%30dd%36%38%33c%37%37a%33d%33%35%31%34bd%34%30%30d%30%35%2Fdocument%2FX%31HUK%35A%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/bcite/X1HUK5A003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/bcite/X1HUK5A003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/bcite/X1HUK5A003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/related_content/X1HUK5A003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1716516093955";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">684 F.3d 1253</div>
<div class="cite" data-cite-type="ReporterOfDecisions">103 U.S.P.Q.2d 1250</div>
<div class="cite" data-cite-type="DocketNumber">2012-1228</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 163766</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
SCIELE PHARMA INC.(now known as Shionogi Pharma Inc.), Plaintiff-Appellee,
and Andrx Corporation, Andrx Pharmaceuticals Inc.(doing Business as Watson
Laboratories Inc.-Florida), Andrx Pharmaceuticals L.L.C., Andrx Laboratories
(NJ) Inc., Andrx EU Ltd., and Andrx LABS L.L.C., Plaintiffs, v. LUPIN
LTD.and Lupin Pharmaceuticals Inc., Defendants-Appellants, and Mylan Inc.and
Mylan Pharmaceuticals Inc., Defendants.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2012-1228.
</center></p>
<p><center>
July 2, 2012.
</center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_920929" href="#headnote_ref_pq2-dec_920929">[1]</a> <span>Practice and procedure in Patent and Trademark Office &mdash;
Prosecution &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1716516093955/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=110.0901" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="110.0901">&#9658;110.0901</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1716516093955/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.01" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.01">&#9658;115.01</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Burden of proof </span> <a href="http://www.bloomberglaw.com/document/1716516093955/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.35" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.35">&#9658;410.35</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Under 35 U.S.C. &sect;282, presumption of validity attaches to all issued patents, and claims of invalidity with respect to issued patent must be proved by clear and convincing evidence, which reflects high burden of proof created by necessary deference to U.S. Patent and Trademark Office; there is no heightened or added burden that applies to invalidity defenses based on references that were before PTO, and instead, fact that references were previously before PTO goes to weight of evidence; in present case, claims of asserted patent will not be held to have been improperly issued based on unusual prosecution history, wherein claims that were rejected and cancelled as unpatentable in view of prior art before examiner were nevertheless included in patent that issued, since rejection of issued claims would be inconsistent with Section 282 presumption of validity, but obviousness analysis will take into account prosecution history, including fact that prior art references were before PTO, and bizarre circumstances surrounding issuance of claims.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_920930" href="#headnote_ref_pq2-dec_920930">[2]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Combining references </span> <a href="http://www.bloomberglaw.com/document/1716516093955/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0905" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0905">&#9658;115.0905</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<span>Non-monetary and injunctive &mdash; Equitable relief &mdash;
Preliminary injunctions &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1716516093955/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0707.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0707.07">&#9658;505.0707.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court abused its discretion by issuing preliminary injunction barring defendant from selling generic version of extended-release tablet of metaformin hydrochloride alleged to infringe patent in suit, since first of two prior art references before U.S. Patent and Trademark Office discloses all limitations of asserted claims except range for mean time to maximum plasma concentration of drug (T<sub>max</sub>), since second prior art reference discloses median T<sub>max</sub>, but provides raw data from which person skilled in art could compute range of possible mean T<sub>max</sub> values, thereby teaching skilled artisan to lower T<sub>max</sub> disclosed in first reference, since second reference describes benefits that earlier release, resulting in lower T<sub>max</sub>, would provide, and such benefits would motivate person skilled in art to modify first reference to achieve lower T<sub>max</sub> range, which better matches profile of industry standard drug while providing convenience of extended release, and since applicant's characterization of predictability and skill in art during prosecution provides further evidence that it would have been routine and obvious design choice to make extended release dosage form of drug with lower T<sub>max</sub>.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of Delaware,
Robert B. Kugler, J.
</p></div>
<span CLASS="page_no" data-cite="684 f 3d 1254" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1254" data-primary-citation="684 F.3d 1253">[*1254]</span> <div id="para2" printdualcolumn="true"><p>
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="684 f 3d 1255" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1255" data-primary-citation="684 F.3d 1253">[*1255]</span> 
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="103 uspq 2d 1251" data-cite-type="ReporterOfDecisions" data-cite-pageno="1251" data-primary-citation="103 U.S.P.Q.2d 1250">[**1251]</span> David B. Bassett, Wilmer Cutler Pickering Hale and Dorr LLP, of New York,
NY, argued plaintiff-appellee. With him on the brief were David A.
Manspeizer and Christopher
<span CLASS="page_no" data-cite="684 f 3d 1256" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1256" data-primary-citation="684 F.3d 1253">[*1256]</span> 
R. Noyes; and Mark C. Fleming, of Boston, MA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Douglass C. Hochstetler, Kelley Drye &amp; Warren LLP, of Chicago, IL, argued
for defendants-appellants. With him on the brief was Beth D. Jacob, of New
York, NY. Of counsel was Clifford Katz.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before LOURIE, PROST, and MOORE, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
MOORE, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Lupin Ltd. and Lupin Pharmaceuticals Inc. (collectively Lupin) submitted
an Abbreviated New Drug Application (ANDA) to the Food and Drug
Administration seeking approval to market a generic version of Fortamet, an
extended-release tablet of metformin hydrochloride. Shionogi Pharma
Inc.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> (Shionogi), which markets Fortamet, sued Lupin for
patent infringement under
<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A) asserting, among others, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">U.S. Patent No. 6,
866, 866</a> (&prime;866 patent), which is listed in the Approved Drug Products with
Therapeutic Equivalence Evaluations (Orange Book) entry for Fortamet. Lupin
attempted to launch its generic Fortamet "at risk," i.e., without a final
judgment on the merits in the litigation. Shionogi moved for a preliminary
injunction to stop Lupin from selling its generic Fortamet and the district
court granted Shionogi's request for injunctive relief. For the reasons
discussed below, we <i>vacate</i>the preliminary injunction and <i>remand</i>for further
proceedings consistent with this opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;866 patent is entitled "Controlled Release Metformin Compositions"
and describes and claims, <i>inter alia</i>, dosage forms with "a mean time to
maximum plasma concentration (T <sub>max</sub>) of the drug which occurs at 5.5 to 7.5
hours after oral administration on a once-a-day basis to human patients."
&prime;866 patent, at [57]; <i>see also</i>col.21 11.48-59. Other claims narrow the T
<sub>max</sub>range to, for example, between 5.5 and 7.0 hours after the administration
of the dose of metformin. &prime;866 patent col.21 11.64-67. Shionogi asserted
claims 1, 3, 4, 5, and 25 in this litigation. Claim 3 is the only asserted
claim explicitly limited to a narrower T <sub>max</sub>range.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The claimed T <sub>max</sub>range reflects a quirk in the &prime;866 patent's prosecution
history. During prosecution, the examiner rejected a number of pending
claims as obvious in light of WO 99/47125 (Cheng) in view of U.S. Patent No.
3,845,770. J.A. 2634. In a subsequent examiner interview, the applicant
discussed the "importance of T <sub>max</sub>. . . and the relationship to
gluconeogenesis," and the examiner indicated that the "closest prior art" &mdash;
Cheng <span CLASS="page_no" data-cite="2012 bl 163766 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> &mdash; "suggest[s] the general teaching of a T <sub>max</sub>of 8." J.A. 2643. In
response, the applicant cancelled a number of claims including claim 1,
which had an upper T <sub>max</sub>range of 7.5 hours, and rewrote then-pending claim
5, which had an upper T <sub>max</sub>range of 7 hours, into independent form. J.A.
2668. The applicant indicated that the examiner agreed during the interview
"that [pending] claim 5, which had an upper T <sub>max</sub>of 7.0 hours and which
value is directly supported by the working examples, is patentably distinct
over the Cheng, et al. reference." J.A. 2675.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Despite cancelling the rejected claims including claim 1, the applicant
received a notice of allowance for pending claims 1, 4, 5, 7-27, and 29.
J.A. 2645. The applicant contacted the Patent Office and explained that the
notice of allowance mistakenly
<span CLASS="page_no" data-cite="684 f 3d 1257" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1257" data-primary-citation="684 F.3d 1253">[*1257]</span> 
allowed cancelled claims, including the previously cancelled claim 1. J.A.
2650. The applicant provided "a listing of the pending claims," which once
again indicated that claim 1 was cancelled. <i>Id.</i>The examiner issued a
supplemental notice of allowance acknowledging the amendment after the
interview, removing the cancelled claims, and allowing the amended claims.
J.A. 2686. The supplemental notice of allowance thus accurately reflected
the applicant's <span CLASS="page_no" data-cite="103 uspq 2d 1252" data-cite-type="ReporterOfDecisions" data-cite-pageno="1252" data-primary-citation="103 U.S.P.Q.2d 1250">[**1252]</span> prior submission: the pending claims directed to a T <sub>max</sub>with
an upper limit of 7.5 hours (including claim 1) were "[c]ancelled," J.A.
2668, and claims 5, 7-27, 29, 30, and 43 (with an upper T <sub>max</sub>of 7 hours)
were allowed, J.A. 2668-73.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After this, the &prime;866 patent issued with a surprise; the issued, patent
contained the cancelled claims from the first notice of allowance &mdash; not the
supplemental notice of allowance. Hence, the patent issued with claim 1's
original upper T <sub>max</sub>limit of 7.5 hours, the exact T <sub>max</sub>limit that the
examiner found problematic, and that the applicant sought to avoid by
cancelling pending claim 1. J.A. 2675. After issuance, the patentee did not
pursue further action, and claim 1 of the issued patent continues to recite
the higher T <sub>max</sub>limit of 7.5 hours. Because claim 1 is the only independent
claim in the patent, many of the dependent claims also include the
limitation that the upper end of the T <sub>max</sub>range is 7.5 hours.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;866 patent was eventually listed in the Orange Book entry for
Fortamet. When Lupin filed its ANDA seeking permission to sell a generic
version of Fortamet, the application included a Paragraph IV certification
that the &prime;866 patent was invalid, unenforceable, and/or would not be
infringed by Lupin's ANDA products. Shionogi filed a suit for patent
infringement within the requisite time period, thereby triggering the
statutory 30-month stay of FDA approval of Lupin's ANDA. Although the
patentee previously sought on several occasions to cancel -what essentially
issued as claim 1 in the &prime;866 patent, Shionogi nevertheless asserted claim
1, along with claims 3-5 and 25, in the present litigation. Claim 3 is the
only asserted claim limited to dosage forms with an upper T <sub>max</sub>of 7 hours.
The other claims have an upper T <sub>max</sub>limit of 7.5 hours. The litigation
progressed but remained unresolved when the 30-month stay expired. The
expiration of the 30-month stay allowed <span CLASS="page_no" data-cite="2012 bl 163766 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> the FDA to give final approval to
Lupin's ANDA on June 29, 2011, and Lupin launched its ANDA product on
September 30, 2011. Shionogi moved for a preliminary injunction and a recall
of Lupin's generic products on October 12, 2011.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On December 6, 2011, the district court-granted a preliminary injunction
that prohibited Lupin from "further importation and sales of its generic
version of . . . Fortamet." J.A. 1. After reviewing the standard for a
preliminary injunction, the court held that Shionogi was likely to prevail
on its infringement claim based primarily on Lupin's proposed labeling. J.A.
11. The court then rejected Lupin's argument that the claims of the &prime;866
patent were improperly issued. J.A. 12. Although the court did not reach the
merits of Lupin's obviousness arguments, it did note that in light of the
presumption of validity and "the very steep requirement that the Defendant
show clear and convincing evidence of the invalidity of Plaintiffs patent,
the factual dispute concerning the prosecution of the &prime;866 patent is not
sufficient to persuade the Court to resolve the question of validity in
Defendant's favor at this preliminary stage." J.A. 12.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Lupin appealed. We vacated the preliminary injunction and remanded it to
the district court because the "district court's order imposing the
preliminary injunction
<span CLASS="page_no" data-cite="684 f 3d 1258" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1258" data-primary-citation="684 F.3d 1253">[*1258]</span> 
failed to even address Lupin's obviousness arguments." <i>Sciele Pharma Inc. v.</i>
<i>Lupin Ltd.</i>, No. 2012-1118, 2012 U.S.App. LEXIS 2442, at *2 (Fed.Cir. Feb. 6,
2012). In particular, we noted that the "district court did not make any
findings of fact or any conclusions of law regarding Lupin's obviousness
arguments." <i>Id.</i>at *2-3. We further indicated that the "fact that prior art
was before the PTO can not be the only reason to reject an obviousness
defense," and that "Lupin is entitled to have the district court make an
independent assessment of its defense and apply the proper burden of proof."
<i>Id.</i>at *3. We remanded for the district court to make appropriate findings
and conduct an appropriate obviousness analysis in the first instance. <i>Id.</i>at
*4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On remand the district court noted that although Lupin's obviousness
"argument relies heavily on the Supreme Court's ruling in <i>KSR</i>," there is "a
fundamental factual difference between this case and <i>KSR International Co.</i>
<i>v. Telefax, Inc.</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007) &mdash;
namely, that in this case the prior art allegedly rendering the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 Patent</a>
obvious was considered by the Patent and Trademark Office . . . when it
approved the &prime;866 Patent." <i>Sciele Pharma Inc. v. Lupin Ltd.</i>, No. <cite>09-0037</cite>,
<cite>2012 U.S. Dist. LEXIS 22782</cite>, at *9-10 (D.Del. Feb. 14, 2012). The court also
pointed out that during the prosecution of the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a>, "the PTO not
only had the opportunity to consider the prior art taught by Cheng, but in
fact did consider it." <i><cite>Id</cite>.</i>at *11. The other prior art reference relied upon
by Lupin, Timmins (W099/47128), was also "before the PTO when the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866
Patent</a> was approved." <i><cite>Id</cite>.</i>at *12. The court found it important that Timmins
teaches a <i>median</i>T <sub>max</sub>while the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a> claims a <i>mean</i>T <sub>max</sub><i><cite>Id</cite>.</i>at *12-13.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span CLASS="page_no" data-cite="103 uspq 2d 1253" data-cite-type="ReporterOfDecisions" data-cite-pageno="1253" data-primary-citation="103 U.S.P.Q.2d 1250">[**1253]</span> The district court also drew three legal conclusions. First, the court
concluded that it was required to defer to the PTO as a "qualified
government agency," notwithstanding the odd sequence of events that gave
rise to the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a>. <i><cite>Id</cite>.</i>at *17. The court explained that because <span CLASS="page_no" data-cite="2012 bl 163766 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> the
prior art references were previously before the PTO, Lupin faced an "`added
burden of overcoming the deference that is due to a qualified government
agency presumed to have done its job.'" <i><cite>Id</cite>.</i>at *16 &mdash; 17 (quoting <i>PharmaStem</i>
<i>Therapeutics, Inc. v. Viacell, Inc.</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1798CG003?jcsearch=491%20f%203d%201342&amp;summary=yes#jcite">491 F.3d 1342</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1798CG003?jcsearch=491%20f%203d%201342&amp;summary=yes#jcite">1366</a> (Fed.Cir.2007)).
Second, the court held that <i>KSR</i>was not directly applicable to the current
case because the prior art was before the PTO when the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a> issued.
<i>Sciele</i>, <cite>2012 U.S. Dist. LEXIS 22782</cite>, at *18. In its analysis, the court
focused on the disclosure of a median, not mean, T <sub>max</sub>in Timmins and
concluded the differences between Timmins, Cheng, and the claimed invention
were too great in light of "the deference owed to the PTO's assessment of
the prior art before it." <i><cite>Id</cite>.</i>at *19. Finally, the court rejected Lupin's
argument that statements from the prosecution regarding enablement could
also be used as proof of obviousness. <i><cite>Id</cite>.</i>at *20-21. The court then
reinstated the preliminary injunction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Lupin moved for a stay of the preliminary injunction, which the district
court denied. Lupin then appealed the grant of the preliminary injunction to
our court and moved for a stay of the injunction. We have jurisdiction
pursuant to <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEIMUA003?jcsearch=28%20U.S.C.%20%201292(c)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1292</a>(c)(1). We ordered expedited briefing, held oral
arguments on the merits of the appeal, and granted Lupin's request for a
stay of the injunction. We now explain how the district court's erroneous
interpretation of the law led it to incorrectly grant a preliminary
injunction in this case.
<span CLASS="page_no" data-cite="684 f 3d 1259" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1259" data-primary-citation="684 F.3d 1253">[*1259]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review a decision to grant a preliminary injunction for abuse of
discretion. <i>Abbott Labs. v. Sandoz, Inc.</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1B3VRC003?jcsearch=566%20f%203d%201282&amp;summary=yes#jcite">566 F.3d 1282</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1B3VRC003?jcsearch=566%20f%203d%201282&amp;summary=yes#jcite">1298</a>
(Fed.Cir.2009). To constitute an abuse of discretion, a district court
decision must either make a clear error of judgment in weighing relevant
factors or exercise discretion based upon an error of law. <i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1B3VRC003?jcsearch=566%20F.3d%201282&amp;summary=yes#jcite">Id</a>.</i>To the extent
the court's decision is based upon an issue of law, we review that issue <i>de</i>
<i>novo. Sanofi-Synthelabo v. Apotex, Inc.</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">470 F.3d 1368</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">1374</a> (Fed.Cir.2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In deciding whether to grant a preliminary injunction, a district court
assesses four factors: "(1) a reasonable likelihood of success on the
merits; (2) irreparable harm if an injunction is not granted; (3) a balance
of hardships tipping in its favor; and (4) the injunction's favorable impact
on the public interest." <i>Amazon.com, Inc. v. Barnesandnoble.com, Inc.</i>,
<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">239 F.3d 1343</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">1350</a> (Fed.Cir.2001). To demonstrate a likelihood of success
on the merits, a patentee must show that, in light of the presumptions and
burdens that will inhere at trial on the merits: (1) the patentee will
likely prove that the accused infringer infringes the asserted patent; and,
(2) the patentee's infringement claim will likely withstand the accused
infringer's challenges to the validity and enforceability of the patent. <i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X50EPD?jcsearch=239%20F.3d%201343&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      A patent is obvious "if the differences between the subject matter
    sought to be patented and the prior art are such that the subject
    matter as a whole would have been obvious at the time the invention
    was made to a person having ordinary skill in the art to which said
    subject &bull; matter pertains." <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a). Whether a patent
    claim is obvious is ultimately a question of law based on underlying
    facts:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Under <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a>, the scope and content of the prior art are <span CLASS="page_no" data-cite="2012 bl 163766 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> to be
    determined; differences between the prior art and the claims at
    issue are to be ascertained; and the level of ordinary skill in the
    pertinent art resolved. Against this background, the obviousness or
    non-obviousness of the subject matter is determined. Such secondary
    considerations as commercial success, long felt but un-solved needs,
    failure of others, etc., might be utilized to give light to the
    circumstances surrounding the origin of the subject matter sought to
    be patented.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Graham v. John Deere Co. of Kansas City</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17-18</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/1?citation=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>,
<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a> (1966). The obviousness analysis entails "an expansive and
flexible approach." <i>KSR</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 415</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>. "If a person of
ordinary skill can implement a predictable variation, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a> likely bars its
patentability." <i>Id.</i>at 417, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>. Ultimately, "a court must ask
whether the improvement is more than the predictable use of prior art
elements according to their established functions." <i>Id.</i>There need not be
"precise teachings directed to the specific subject matter of the challenged
claim, for a court can take account of the inferences and creative steps
that a person of ordinary skill in the art would employ." <i>Id.</i>at 418,
<span CLASS="page_no" data-cite="103 uspq 2d 1254" data-cite-type="ReporterOfDecisions" data-cite-pageno="1254" data-primary-citation="103 U.S.P.Q.2d 1250">[**1254]</span> <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I. The Presumption of Validity
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_920929" href="#headnote_pq2-dec_920929">[1]</a> Both parties argue that the presumption of validity and the accompanying
burden of proof is altered due to the facts of this case. Lupin, who
challenges the validity of the patent, argues that the presumption of
validity should not attach because of the erroneous issuance of the
cancelled claims. Shionogi argues that there should be a heightened
presumption of validity because the prior art references relied upon by
Lupin (Cheng and Timmins) were before the Patent Office during
<span CLASS="page_no" data-cite="684 f 3d 1260" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1260" data-primary-citation="684 F.3d 1253">[*1260]</span> 
prosecution. Both parties are wrong. The presumption of validity attaches to
all issued patents and the clear and convincing evidence burden applies to
all issued patents. Under <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEJ050003?jcsearch=35%20usc%20282&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a>, an issued patent "shall be
presumed valid," but this presumption can be rebutted. <i>Chore-Time Equip.,</i>
<i>Inc. v. Cumberland Corp.</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X3UPP3?jcsearch=713%20f%202d%20774&amp;summary=yes#jcite">713 F.2d 774</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X3UPP3?jcsearch=713%20f%202d%20774&amp;summary=yes#jcite">780</a> (Fed.Cir.1983). The presumption
of validity found in <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEJ050003?jcsearch=35%20U.S.C.%20%20282&amp;summary=yes#jcite">&sect; 282</a> is reflected in the standard of proof required to
prove invalidity, clear and convincing evidence. <i>Microsoft Corp. v. i4i Ltd.</i>
<i>P'ship</i>, ___ U.S.___, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2245-46</a>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a> (2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court is correct that there is a "high burden of proof
created by the necessary deference to the PTO." <i>Sciele</i>,
<cite>2012 U.S. Dist. LEXIS 22782</cite>, at *21. This notion stems from our suggestion
that the party challenging a patent in court "bears the added burden of
overcoming the deference that is due to a qualified government agency
presumed to have done its job." <i>PharmaStem</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1798CG003?jcsearch=491%20f%203d%201342&amp;summary=yes#jcite">491 F.3d at 1366</a> (internal
quotation marks omitted). That high burden is reflected in the clear and
convincing evidence burden for proving invalidity. <i>See i4i</i>131 S.Ct. at 2246
(The presumption of validity creates "`a heavy burden of persuasion,'
requiring proof of the defense by clear and convincing evidence. . . . [T]he
presumption encompassed not only an allocation of the burden of proof but
also an imposition of a heightened standard of proof.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whether a reference was previously considered by the PTO, the burden of
proof is the same: clear and convincing evidence of invalidity. <i>See </i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">id.at
2250</a> ("Nothing in <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEJ050003?jcsearch=35%20U.S.C.%20%20282&amp;summary=yes#jcite">&sect; 282</a>'s text suggests that Congress meant . . . to enact a
standard of proof <span CLASS="page_no" data-cite="2012 bl 163766 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> that would rise and fall with the facts of each case.").
As the Supreme Court explained in <i>i4i</i>there is no heightened burden of proof
when a reference was previously considered by the PTO, and no lowered burden
of proof if a defendant raises a new reference or argument during
litigation. <i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">Id</a>.</i>The burden does not suddenly change to something higher &mdash;
"extremely clear and convincing evidence" or "crystal clear and convincing
evidence" &mdash; simply because the prior art references were considered by the
PTO. In short, there is no heightened or added burden that applies to
invalidity defenses that are based upon references that were before the
Patent Office. The burden is always the same, clear and convincing evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the ultimate burden of proof does not change, new evidence not
considered by the PTO "may `carry more weight' . . . than evidence
previously considered by the PTO," and may "`go further toward sustaining
the attacker's unchanging burden.'" <i></i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">Id.at 2251</a> (quoting <i>Am. Hoist &amp; Derrick</i>
<i>Co. v. Sowa &amp; Sons, Inc.</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XABMGJ?jcsearch=725%20f%202d%201350&amp;summary=yes#jcite">725 F.2d 1350</a> (Fed.Cir.1984)). "[I]f the PTO did
not have all material facts before it, its considered judgment may lose
significant force" and the burden to persuade the finder of fact by clear
and convincing evidence may, therefore, "be easier to sustain." <i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">Id</a>.</i>Instead,
the fact that references were previously before the PTO goes to the weight
the court or jury might assign to the proffered evidence. <i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For example, it could be reasonable to give more weight to new arguments
or references that were not explicitly considered by the PTO when
determining whether a defendant met its burden of providing clear and
convincing evidence of invalidity. <i><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">Id</a>.</i>Conversely, it may be harder to meet
the clear and convincing burden when the invalidity contention is based upon
the same argument on the same reference that the PTO already considered.
Importantly, whether a reference was before the PTO goes to the weight of
the evidence, and the
<span CLASS="page_no" data-cite="684 f 3d 1261" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1261" data-primary-citation="684 F.3d 1253">[*1261]</span> 
parties are of course free to, and generally do, make these arguments to the
fact finder. But the presumption of validity and accompanying burden of
proof, clear and convincing evidence, are not altered.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Lupin's argument that we should hold that the claims of the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a>
were improperly issued is similarly unavailing. Lupin's position, that we
should reject the issued claims of the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a> because of the quirks in
the prosecution history, is inconsistent with the presumption of <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XEJ050003?jcsearch=35%20U.S.C.%20%20282&amp;summary=yes#jcite">&sect; 282</a>. The
presumption applies to all issued claims. That does not mean, however, that
we should not consider the prosecution history. We can take it all into
account, including both the fact that the Cheng and Timmins references were
before the Patent Office and the bizarre circumstances surrounding the
issuance of the claims in this patent. Other than recognizing that the
prosecution <span CLASS="page_no" data-cite="103 uspq 2d 1255" data-cite-type="ReporterOfDecisions" data-cite-pageno="1255" data-primary-citation="103 U.S.P.Q.2d 1250">[**1255]</span> history was "puzzling," the district court did not discuss the
prosecution history, which demonstrates that the examiner concluded that the
claims with an upper T <sub>max</sub>limit of 7.5 were not patentable in view of Cheng
and that the applicant acquiesced in that conclusion and cancelled those
claims. The Cheng reference <span CLASS="page_no" data-cite="2012 bl 163766 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> was before the Patent Office, and rather than
allow the claims over Cheng, the examiner concluded that claims with an
upper T <sub>max</sub>limit of 7.5 were not allowable in light of Cheng. Yet the
rejected and later cancelled claims with the upper T <sub>max</sub>limit of 7.5 were
ultimately issued by the PTO. We take all of this into account in our
obviousness analysis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II. Cheng In View of Timmins Raises a Substantial Question of Validity
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_920930" href="#headnote_pq2-dec_920930">[2]</a> We conclude that Lupin's obviousness arguments regarding Cheng and
Timmins, considered in light of the prosecution history and the correct
standard of proof, raise a substantial question of invalidity. Lupin argues
that the asserted claims are obvious over Cheng in view of Timmins. Cheng
discloses all of the limitations of the asserted claims except for the T
<sub>max</sub>range of 5.5 to 7.5 hours (Cheng discloses a T <sub>max</sub>of 8 to 12 hours).
Lupin asserts that Timmins discloses a T <sub>max</sub>within the range recited in the
asserted claims, and argues that the combination of Cheng and Timmins thus
renders the claims obvious to one skilled in the art. As further evidence
that the combination would be obvious to one of ordinary skill in the art,
Lupin points to the applicant's assertion during prosecution "that one
skilled in the art would be able to manipulate the processes and
formulations of the [prior art] by other methods to obtain the claimed
pharmacokinetic parameters of the present invention by routine
experimentation." J.A. 2621. Lupin claims that this statement amounts to an
admission of obviousness and further bolsters its obviousness claim.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Shionogi argues that the T <sub>max</sub>range of the asserted claims is missing from
Cheng, but does not dispute that Cheng discloses the other limitations of
the asserted claims. Its primary distinction with respect to Timmins is that
Timmins discloses a <i>median</i>T <sub>max</sub>and not the claimed <i>mean</i>T <sub>max</sub>. Shionogi
further argues that, regardless of the T <sub>max</sub>disclosed in Timmins, there is
no motivation to combine Cheng with Timmins.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We agree with Lupin that it has raised, a substantial question of validity
with respect to the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a>. <i>Amazon.com</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">239 F.3d at 1350</a>. We conclude
that the district court's obviousness analysis was flawed. It failed to
correctly apply <i>KSR</i>focusing on what it perceived was "a fundamental factual
difference between this case and <i>KSR</i>," namely that Cheng and Timmins were
before the PTO during prosecution. <i>Sciele</i>, <cite>2012 U.S. Dist. LEXIS 22782</cite>, at
*9-10; * 17-20.
<span CLASS="page_no" data-cite="684 f 3d 1262" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1262" data-primary-citation="684 F.3d 1253">[*1262]</span> 
The court incorrectly rejected Lupin's substantive arguments regarding
Timmins's disclosure of a T <sub>max</sub>within the claimed range and the motivation
to combine Cheng and Timmins.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;866 patent admits that Cheng "discloses controlled release metformin
formulations providing a T <sub>max</sub>from 8 to 12 hours." &prime;866 patent col.2
11.46-47. Although Timmins expressly discloses a median T <sub>max</sub>, it also
provides the raw data from which one skilled in the art could compute the
range of possible mean T <sub>max</sub>values. J.A. 2501-02.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>Based on this data,
one skilled in the art would understand that the mean T <sub>max</sub>in Timmins must
fall between 4.67 and 6.33 hours. Counsel for Shionogi agreed that the only
element missing from <span CLASS="page_no" data-cite="2012 bl 163766 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> Cheng is the T <sub>max</sub>range, and that Timmins discloses a
range of possible mean T <sub>max</sub>between 4.67 and 6.33 hours. <i>See</i>Oral Argument at
19:55-20:33, <i>available</i>
<i>at</i>http://www.cafc.uscourts.gov/oral-argument-recordings/2012-1228 /all.
Timmins thus teaches one skilled in the art to lower the T <sub>max</sub>of Cheng (8
hours).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We also conclude that the district court clearly erred in its conclusion
that there was no motivation to combine Cheng and Timmins. Timmins describes
a controlled release formulation of metformin and explains that its
formulation releases metformin in the portion of the gastrointestinal tract
where better absorption of the drug can occur. J.A. 2470-73. The earlier
release of the drug increases bioavailability and leads to a lower T <sub>max</sub>.
<i>Id.</i>Timmins explains that "improved bioavailability from an extended release
dosage form that releases metformin at a rate likely to provide the desired
plasma levels of drug for an extended time period [could result] from a
dosage form that has extended residence time in the upper gastrointestinal
tract." J.A. 2472-73. In other words, that earlier release, resulting in a
lower T <sub>max</sub>. provides the benefit of "the desired plasma levels of drug for
an extended <span CLASS="page_no" data-cite="103 uspq 2d 1256" data-cite-type="ReporterOfDecisions" data-cite-pageno="1256" data-primary-citation="103 U.S.P.Q.2d 1250">[**1256]</span> time period." <i>Id.</i>Timmins also identifies a number of benefits
stemming from an earlier extended release, including "reduction in dosing
frequency, providing patient convenience that would probably improve
compliance" as well as "an extended time period over which therapeutically
beneficial plasma levels of drug were maintained." <i>Id.</i>These benefits would
motivate one skilled in the art to modify Cheng to achieve a lower T
<sub>max</sub>range. <i>Cf. KSR.</i>550 U.S. at 424, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Further motivation to pursue the approach in Timmins comes from the fact
that lowering the T <sub>max</sub>allows one skilled in the art to approach the drug
profile of Glucophage, the industry standard drug. J.A. 2469. In fact,
Timmins expressly compares its extended release formulations to Glucophage
with respect to various factors including T <sub>max</sub>. J.A. 2502. Timmins explains
that, in light of this analogous kinetic profile and other identified
benefits, the "formulations of the invention thus represent a useful advance
in the administration of metformin hydrochloride to human[s] in the
treatment of diabetes." <i>Id.</i>Timmins thus articulates an explicit motivation
to lower the T <sub>max</sub>in Cheng &mdash; to better match the T <sub>max</sub>profile of Glucophage
while providing the convenience of an extended release.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The applicant's arguments during prosecution further buttress our belief
that Lupin has raised a substantial question of validity with respect to the
&prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a>. During prosecution the applicant indicated "that one skilled in
the art would be able
<span CLASS="page_no" data-cite="684 f 3d 1263" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1263" data-primary-citation="684 F.3d 1253">[*1263]</span> 
to manipulate the processes and formulations of the [prior art] by other
methods to obtain the claimed pharmacokinetic parameters of the present
invention by routine experimentation." J. A. 2621. While Shionogi argued,
and the district court seemed to accept, that this statement applies only to
enablement, we are hard pressed to understand this distinction. Coupled with
the motivation <span CLASS="page_no" data-cite="2012 bl 163766 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> to lower the T <sub>max</sub>, as disclosed in Timmins, the applicant's
characterization of the predictability and skill in the art during
prosecution provides further evidence that it would have been a routine and
obvious design choice to make an extended release dosage form with a lower T
<sub>max</sub>. After all, "[i]f a person of ordinary skill can implement a predictable
variation, &sect; 103 likely bars its patentability." <i>KSR</i>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 417</a>,
<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Shionogi fails to effectively rebut Lupin's argument that Timmins itself
supplies a motivation to modify Cheng to lower the T <sub>max</sub>of a controlled
release formulation to match that of an immediate release formulation.
Likewise, Shionogi does not establish that Lupin's arguments regarding the
advantages of the lower T <sub>max</sub>disclosed in Timmins are unsound. We therefore
believe the combination of Cheng and Timmins raises a substantial question
as to the validity of the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a>. <sub>Amazon.com</sub>, <a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">239 F.3d at 1350</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because the district court incorrectly concluded that Lupin failed to
raise a substantial question of validity regarding the asserted claims of
the &prime;<a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X320OC831GJ?jcsearch=usp%206866866&amp;summary=yes#jcite">866 patent</a>, it abused its discretion by issuing a preliminary
injunction enjoining Lupin from selling its generic product. Accordingly, we
vacate the preliminary injunction and remand to the district court for
further proceedings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>VACATED and REMANDED.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  COSTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Costs to Defendants-Appellants.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> Scielc Pharma Inc. is now known as Shionogi Pharma. For simplicity wc
will refer only to Shionogi in this opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> Timmins discloses that its study included 24 hours, with a minimum T
<sub>max</sub>of 4 hours and a patients and resulted in a median T <sub>max</sub>of 5 maximum T
<sub>max</sub>of 8 hours.
</p></div>
</div>
<!--BBLS DD 1716516093955-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HUK5A003/history">Direct History (5)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HUK5A003/analysis">Case Analysis (12)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HUK5A003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
12
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Injunction Vacated, Case Remanded</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceutical Manufacturing</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/197e26ee0dd683c77a3d3514bd400d05/document/X1Q6M5I6MOO2">12-01228 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/197e26ee0dd683c77a3d3514bd400d05/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "197e26ee0dd683c77a3d3514bd400d05";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY0bdd3d&previousPageId=&previousActivityInstanceId=ENTITY1f2d18&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:57:19-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HUK5A003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY1f2d18&previousPageId=&previousActivityInstanceId=ENTITYf9bb3b&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:57:16-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HUK5A003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HUK5A003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","1718421","4063892"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
